Michael Harwood

1 Zimmer L. Hillen U. Livingstone E. et al. Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. In 2011, the Food and Drug Administration approved vemurafenib, a class 1 RAF inhibitor that is selective for BRAF, for use in unresectable or metastatic malignant melanoma. The BRAF V600E mutation is found in roughly 80%-90% of BRAF-mutated melanomas, and in about 50% of overall melanomas., 2 Göppner D. Müller J. Krüger S.

Michael Harwood is a freelance writer who reports frequently on science and the environment. The theoretical physicist, although he deals in such arcane, modern concepts as curved time and space, is part of a philosophical and spiritual tradition older than recorded history. He seeks to know not just life as he experiences it but how the hidden parts of the universe work and fit together. Ultimately he hopes to learn if and how and why the universe began and if and how and why it will end.